What are the normal C‑peptide levels (fasting and after glucagon or mixed‑meal stimulation)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Normal C-Peptide Levels

Normal fasting C-peptide levels should be suppressed to <0.6 ng/mL (200 pmol/L) when glucose falls below 55 mg/dL (3.0 mmol/L), while in healthy individuals at normal glucose levels, fasting C-peptide typically ranges from 0.8-1.0 ng/mL (approximately 267-333 pmol/L). 1

Fasting C-Peptide Reference Values

In Healthy Individuals

  • Pre-pubertal children: Median fasting C-peptide of 0.8 nmol/L (approximately 2.4 ng/mL) 2
  • Pubertal children and adults: Median fasting C-peptide of 0.9-1.0 nmol/L (approximately 2.7-3.0 ng/mL) 2
  • Adults: Fasting values of 1.53 ± 0.16 ng/mL in control subjects 3

Clinical Context Matters

The interpretation of C-peptide levels is highly dependent on the concurrent glucose level. The American consensus and Endocrine Society guidelines establish that C-peptide should be <0.6 ng/mL (200 pmol/L) when glucose is <55 mg/dL (3.0 mmol/L) to be considered appropriately suppressed. 1 This threshold has nearly 100% sensitivity and specificity for diagnosing inappropriate insulin secretion when glucose is ≤45 mg/dL (2.5 mmol/L). 1

Stimulated C-Peptide Values

After Glucagon Stimulation

  • Pre-pubertal children: Rise from 0.8 to 1.9 nmol/L (approximately 5.7 ng/mL) 2
  • Pubertal children and adults: Rise from 0.9-1.0 to 2.7 nmol/L (approximately 8.1 ng/mL) 2
  • Adults: Peak values of 241.6 ± 20.3 ng/ml·min (area under curve) in controls 3

After Mixed-Meal Stimulation

  • Adults: Peak C-peptide of 2,873 ± 210 pmol/L (approximately 8.6 ng/mL) in control subjects 4
  • Area under curve: 204.7 ± 15.6 ng/ml in controls 3

Important Clinical Caveats

Measurement Timing and Conditions

C-peptide must be measured with a concurrent glucose level >72 mg/dL (4 mmol/L), as hypoglycemia will suppress C-peptide secretion. 5 For individuals with DKA or severe hyperglycemia, wait at least 2 weeks after resolution of glucotoxicity before measuring C-peptide. 5

Diabetes Classification Thresholds (ADA/EASD Consensus)

  • <0.6 ng/mL (200 pmol/L) within 5 hours of a meal in individuals <35 years with ≥1 positive type 1 diabetes antibody suggests type 1 diabetes 5
  • ≥1.8 ng/mL (600 pmol/L) in adults >35 years taking insulin is most consistent with type 2 diabetes 5
  • 0.6-1.8 ng/mL (200-600 pmol/L) is indeterminate and requires additional clinical context 5

Assay Variability Warning

There is significant variability among C-peptide assays, and standardization has not been achieved despite calls for it. 5, 6, 7 Results from different manufacturers show substantial discrepancies, which can have significant consequences for diabetes classification and therapeutic decisions. 7 The defined cut-off values should be interpreted with caution given this lack of standardization.

Conditions Affecting Interpretation

These thresholds were validated in patients without conditions affecting insulin resistance or metabolism. Use caution or alternative testing (beta-hydroxybutyrate, glucagon stimulation) in patients with:

  • Renal insufficiency (thresholds non-applicable) 1
  • Hepatic insufficiency (not validated) 1
  • Post-partial pancreatectomy (not validated) 1
  • Certain genetic forms of nesidioblastosis 1

Unit Conversion

pmol/L is converted to ng/mL by multiplying by 0.003 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.